You are here

FDA Approves Flonase Sensimist as OTC Allergy Treatment

The product was previously available by prescription as Veramyst

The FDA has approved Flonase Sensimist Allergy Relief (fluticasone furoate, 27.5-mcg spray, GlaxoSmithKline) as an over-the-counter (OTC) treatment for symptoms associated with seasonal and perennial allergies. Previously available by prescription as Veramyst, Flonase Sensimist is the latest Rx-to-OTC switch from GSK.

Flonase Sensimist is indicated for the treatment of symptoms associated with seasonal and perennial allergic rhinitis, including sneezing, runny nose, itchy nose, congestion, and itchy, watery eyes, in adults and children 2 years of age and older. The indication for itchy, watery eyes is for individuals 12 years of age and older.

Fluticasone furoate acts on multiple inflammatory substances (histamine, prostaglandins, cytokines, tryptases, chemokines, and leukotrienes). The exact number and precise mechanism are unknown.

Flonase Sensimist will be nationally available in early 2017.

Source: PR Newswire; August 3, 2016.

Recent Headlines

Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs